ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
3 July 2025
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
24 February 2025
A key pivotal study of bemarituzumab will read out shortly.
21 February 2025
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
20 February 2025
US approval could mark the company's graduation to oncology.
20 February 2025
The FDA will rule on a low dose of zongertinib in the summer.
20 February 2025
A triplet did worse than control in first-line kidney cancer.